
## **Richard Beasley MBChB**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7342157/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Single dose of budesonide/formoterol turbuhaler compared to salbutamol pMDI for speed of bronchodilator onset in asthma: a randomised cross-over trial. Thorax, 2023, 78, 745-751.	2.7	9
2	Audit of oxygen administration to achieve a target oxygen saturation range in acutely unwell medical patients. Postgraduate Medical Journal, 2022, 98, 461-465.	0.9	4
3	Epinephrine (adrenaline) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis. Thorax, 2022, 77, 563-572.	2.7	4
4	Experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in a cohort of New Zealand doctors in an oncology setting. Postgraduate Medical Journal, 2022, 98, 35-42.	0.9	5
5	Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study. BMJ Open, 2022, 12, e048537.	0.8	10
6	Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE). ERJ Open Research, 2022, 8, 00570-2021.	1.1	23
7	Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: a randomised crossover trial. European Respiratory Journal, 2022, 60, 2102309.	3.1	4
8	Thoracic Society of Australia and New Zealand Position Statement on Acute Oxygen Use in Adults: â€~Swimming between the flags'. Respirology, 2022, 27, 262-276.	1.3	10
9	Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma. JAMA Network Open, 2022, 5, e220615.	2.8	23
10	How best to share research with study participants? A randomised crossover trial comparing a comic, lay summary, and scientific abstract. Journal of Visual Communication in Medicine, 2022, 45, 172-181.	0.4	2
11	Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. BMJ Open, 2022, 12, e058215.	0.8	7
12	Heart rate variability as a marker of autonomic nervous system activity in young people with eosinophilic and non-eosinophilic asthma. Journal of Asthma, 2022, , 1-9.	0.9	1
13	The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study. Respiratory Medicine, 2022, 200, 106863.	1.3	8
14	Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. New England Journal of Medicine, 2022, 386, 2071-2083.	13.9	55
15	A breath of fresh AIR: reducing the carbon footprint of asthma. Journal of Medical Economics, 2022, 25, 700-702.	1.0	4
16	Conservative or liberal oxygen therapy for mechanically ventilated adults with acute brain pathologies: A post-hoc subgroup analysis. Journal of Critical Care, 2022, 71, 154079.	1.0	4
17	Efficacy of a 3% KÄnuka oil cream for the treatment of moderate-to-severe eczema: A single blind randomised vehicle-controlled trial. EClinicalMedicine, 2022, 51, 101561.	3.2	2
18	Engaging MÄori with qualitative healthcare research using an animated comic. Health Promotion International, 2021, 36, 1170-1177.	0.9	7

#	Article	IF	CITATIONS
19	Budesonide–formoterol reliever therapy in intermittent <i>versus</i> mild persistent asthma. European Respiratory Journal, 2021, 57, 2003064.	3.1	10
20	Searching for the optimal oxygen saturation range in acutely unwell patients. Emergency Medicine Journal, 2021, 38, 168-169.	0.4	1
21	Using comics and curiosity to drive pandemic research on a national scale. Journal of Visual Communication in Medicine, 2021, 44, 12-22.	0.4	9
22	The management of mild asthma. European Respiratory Journal, 2021, 57, 2003051.	3.1	15
23	Asthma in the anti-inflammatory reliever therapy era. Lancet Respiratory Medicine, the, 2021, 9, 118-119.	5.2	3
24	More options for managing severe asthma in adults. Lancet Respiratory Medicine, the, 2021, 9, 3-5.	5.2	7
25	The Vexed Problem of Corticosteroid Toxicity in Asthma: Time for Standardized Assessment. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 373-374.	2.0	5
26	How big is your bubble? Characteristics of self-isolating household units (â€~bubbles') during the COVID-19 Alert Level 4 period in New Zealand: a cross-sectional survey. BMJ Open, 2021, 11, e042464.	0.8	18
27	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. European Respiratory Journal, 2021, 58, 2003927.	3.1	43
28	Balancing the needs of the many and the few: where next for adult asthma guidelines?. Lancet Respiratory Medicine,the, 2021, 9, 786-794.	5.2	18
29	A Proposed Revision of the Stepwise Treatment Algorithm in Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 100-103.	2.5	2
30	Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVIDâ€19 in New Zealand. Arthritis and Rheumatology, 2021, 73, 896-897.	2.9	0
31	Asthma and COVID-19: Preconceptions about Predisposition. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 799-801.	2.5	6
32	Has the time come to end use of the blue inhaler?. Lancet Respiratory Medicine,the, 2021, 9, e51.	5.2	3
33	The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma. ERJ Open Research, 2021, 7, 00271-2021.	1.1	8
34	Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD. BMJ Open, 2021, 11, e053446.	0.8	1
35	Public engagement with clinical research on social media; which visual medium works best? A 5-year retrospective analysis. Journal of Visual Communication in Medicine, 2021, 44, 157-165.	0.4	5
36	Charting a course for the management of long COVID. Lancet Respiratory Medicine,the, 2021, 9, 1358-1360.	5.2	3

#	Article	IF	CITATIONS
37	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
38	Automatic versus manual oxygen titration using a novel nasal high-flow device in medical inpatients with an acute illness: a randomised controlled trial. BMJ Open Respiratory Research, 2021, 8, e000843.	1.2	7
39	Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: AÂrandomized, controlled, proof-of-activity trial. Journal of Allergy and Clinical Immunology, 2021, 148, 783-789.	1.5	27
40	SMART for the treatment of asthma: A network meta-analysis of real-world evidence. Respiratory Medicine, 2021, 188, 106611.	1.3	9
41	ICS-formoterol reliever <i>versus</i> ICS and short-acting β <sub>2</sub> -agonist reliever in asthma: a systematic review and meta-analysis. ERJ Open Research, 2021, 7, 00701-2020.	1.1	32
42	Underestimation of COVID-19 mortality during the pandemic. ERJ Open Research, 2021, 7, 00766-2020.	1.1	47
43	Closed-Loop Oxygen Control Using a Novel Nasal High-Flow Device: A Randomized Crossover Trial. Respiratory Care, 2021, 66, 416-424.	0.8	7
44	Determination of oxygen saturation compared to a prescribed target range using continuous pulse oximetry in acutely unwell medical patients. BMC Pulmonary Medicine, 2021, 21, 332.	0.8	1
45	Enhanced airway sensory nerve reactivity in non-eosinophilic asthma. BMJ Open Respiratory Research, 2021, 8, e000974.	1.2	3
46	Rhinothermy delivered by nasal high flow therapy in the treatment of the common cold: a randomised controlled trial. BMJ Open, 2021, 11, e047760.	0.8	1
47	Nasal gene expression changes with inhaled corticosteroid treatment in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 191-194.	2.7	4
48	Inhaled Corticosteroids in Acute Asthma: A Systemic Review and Meta-Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 605-617.e6.	2.0	25
49	Conservative Oxygen Therapy during Mechanical Ventilation in the ICU. New England Journal of Medicine, 2020, 382, 989-998.	13.9	294
50	The history and future of shortâ€acting beta <sub>2</sub> â€agonist therapy in asthma. Respirology, 2020, 25, 246-248.	1.3	6
51	ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. European Respiratory Journal, 2020, 55, 1901407.	3.1	26
52	Optimal Asthma Control: Time for a New Target. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1480-1487.	2.5	32
53	Twentyâ€five years of <i>Respirology</i> : Advances in asthma. Respirology, 2020, 25, 11-13.	1.3	1
54	Conservative oxygen therapy for mechanically ventilated adults with sepsis: a post hoc analysis of data from the intensive care unit randomized trial comparing two approaches to oxygen therapy (ICU-ROX). Intensive Care Medicine, 2020, 46, 17-26.	3.9	78

#	Article	IF	CITATIONS
55	Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma. European Respiratory Journal, 2020, 55, 1901147.	3.1	27
56	Reducing the burden of asthma: time to set research and clinical priorities. Lancet Respiratory Medicine,the, 2020, 8, 943-944.	5.2	11
57	What matters most to patients when choosing treatment for mild–moderate asthma? Results from a discrete choice experiment. Thorax, 2020, 75, 842-848.	2.7	11
58	Towards a personalised treatment approach for asthma attacks. Thorax, 2020, 75, 1119-1129.	2.7	13
59	Patient preferences for asthma management: a qualitative study. BMJ Open, 2020, 10, e037491.	0.8	15
60	Conservative oxygen therapy for mechanically ventilated adults with suspected hypoxic ischaemic encephalopathy. Intensive Care Medicine, 2020, 46, 2411-2422.	3.9	38
61	Randomised controlled trial of paracetamol or ibuprofen, as required for fever and pain in the first year of life, for prevention of asthma at age 6 years: paracetamol or ibuprofen in the primary prevention of asthma in Tamariki (PIPPA Tamariki) protocol. BMJ Open, 2020, 10, e038296.	0.8	4
62	Influenza control during the COVID-19 pandemic. Lancet, The, 2020, 396, 1633-1634.	6.3	52
63	Achieving the balance between evidence and simplicity. European Respiratory Journal, 2020, 55, 2000651.	3.1	0
64	The effect of 50% oxygen on PtCO2 in patients with stable COPD, bronchiectasis, and neuromuscular disease or kyphoscoliosis: randomised cross-over trials. BMC Pulmonary Medicine, 2020, 20, 125.	0.8	0
65	Self-titration of inhaled corticosteroid and β <sub>2</sub> -agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial. European Respiratory Journal, 2020, 56, 2000170.	3.1	8
66	From Osler to personalized medicine in obstructive airways disease. Respirology, 2020, 25, 781-783.	1.3	2
67	Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respiratory Medicine,the, 2020, 8, 671-680.	5.2	81
68	Antiâ€inflammatory reliever therapy in asthma: The evidence mounts but more is needed. Respirology, 2020, 25, 776-778.	1.3	5
69	Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial. European Respiratory Journal, 2020, 55, 1902073.	3.1	33
70	Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice. Lancet Respiratory Medicine,the, 2020, 8, 425-427.	5.2	1
71	A multicentre prospective observational study comparing arterial blood gas values to those obtained by pulse oximeters used in adult patients attending Australian and New Zealand hospitals. BMC Pulmonary Medicine, 2020, 20, 7.	0.8	31
72	Conservative versus Interventional Treatment for Spontaneous Pneumothorax. New England Journal of Medicine, 2020, 382, 405-415.	13.9	164

#	Article	IF	CITATIONS
73	Management of primary spontaneous pneumothorax: less is more. Lancet, The, 2020, 396, 1973.	6.3	3
74	Medical cannabis: knowledge and expectations in a cohort of North Island New Zealand general practitioners. New Zealand Medical Journal, 2020, 133, 12-28.	0.5	1
75	Asthma and Respiratory Foundation NZ Adolescent and Adult Asthma Guidelines 2020: a quick reference guide. New Zealand Medical Journal, 2020, 133, 73-99.	0.5	3
76	Knowledge and perspectives about the use of cannabis as a medicine: a mixed methods observational study in a cohort of New Zealand general practice patients. New Zealand Medical Journal, 2020, 133, 96-111.	0.5	0
77	Chemical and physical variations of cannabis smoke from a variety of cannabis samples in New Zealand. Forensic Sciences Research, 2019, 4, 168-178.	0.9	16
78	Practice patterns and perceptions of Australian and New Zealand anaesthetists towards perioperative oxygen therapy. Anaesthesia and Intensive Care, 2019, 47, 288-294.	0.2	6
79	Reply to Boulet and Nair: Inhaled Corticosteroids and Adult Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1557-1558.	2.5	0
80	Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet, The, 2019, 394, 919-928.	6.3	180
81	Randomised evaluation of active control of temperature versus ordinary temperature management (REACTOR) trial. Intensive Care Medicine, 2019, 45, 1382-1391.	3.9	13
82	Oxygen: a new look at an old therapy. Journal of the Royal Society of New Zealand, 2019, 49, 126-142.	1.0	7
83	Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Research, 2019, 5, 00036-2018.	1.1	29
84	A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients. Leukemia and Lymphoma, 2019, 60, 1540-1547.	0.6	3
85	Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold. BMJ Open, 2019, 9, e028098.	0.8	2
86	Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. New England Journal of Medicine, 2019, 380, 2020-2030.	13.9	308
87	Nasal highâ€flow therapy compared with nonâ€invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled crossâ€over trial. Respirology, 2019, 24, 1081-1087.	1.3	16
88	Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial. BMJ Open, 2019, 9, e026201.	0.8	40
89	Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. European Respiratory Journal, 2019, 53, 1802058.	3.1	177
90	Asthma paradoxes: time for a new approach across the spectrum of asthma severity. European Respiratory Journal, 2019, 53, 1900218.	3.1	0

#	Article	IF	CITATIONS
91	The Immunological Mysteries of Tuberculosis. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 649-650.	2.0	1
92	Fever control in critically ill adults. An individual patient data meta-analysis of randomised controlled trials. Intensive Care Medicine, 2019, 45, 468-476.	3.9	37
93	Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma. BMC Pulmonary Medicine, 2019, 19, 264.	0.8	7
94	Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1471-1477.	2.5	87
95	Triaging treatable traits in asthma. Respirology, 2019, 24, 5-6.	1.3	4
96	Increased risk of mortality with liberal oxygen therapy compared with conservative oxygen therapy in critically ill adults. BMJ Evidence-Based Medicine, 2019, 24, 113-114.	1.7	4
97	Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1982-1988.e1.	2.0	24
98	Starting betaâ€blockers during exacerbations of chronic obstructive pulmonary disease. Internal Medicine Journal, 2018, 48, 227-228.	0.5	1
99	The inhaled corticosteroid/long-acting l²-agonist maintenance and reliever therapy regimen: where to from here?. European Respiratory Journal, 2018, 51, 1702338.	3.1	4
100	Randomised controlled trial of rhinothermy for treatment of the common cold: a feasibility study. BMJ Open, 2018, 8, e019350.	0.8	4
101	Treatable traits of chronic airways disease. Current Opinion in Pulmonary Medicine, 2018, 24, 24-31.	1.2	24
102	Nasal high flow therapy and PtCO <sub>2</sub> in stable COPD: A randomized controlled crossâ€over trial. Respirology, 2018, 23, 378-384.	1.3	29
103	After asthma: redefining airways diseases. Lancet, The, 2018, 391, 350-400.	6.3	744
104	Serum periostin levels in adults of Chinese descent: an observational study. Allergy, Asthma and Clinical Immunology, 2018, 14, 87.	0.9	9
105	Letting the right one in: evaluating the generalisability of clinical trials. European Respiratory Journal, 2018, 52, 1802218.	3.1	8
106	Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. BMC Pulmonary Medicine, 2018, 18, 157.	0.8	22
107	The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. European Respiratory Journal, 2018, 52, 1800694.	3.1	26
108	Factors associated with body mass index in children and adolescents: An international cross-sectional study. PLoS ONE, 2018, 13, e0196221.	1.1	17

#	Article	IF	CITATIONS
109	Serum periostin levels following small bone fractures, long bone fractures and joint replacements: an observational study. Allergy, Asthma and Clinical Immunology, 2018, 14, 30.	0.9	8
110	Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial. Respiratory Research, 2018, 19, 133.	1.4	17
111	Association between Frequency of Consumption of Fruit, Vegetables, Nuts and Pulses and BMI: Analyses of the International Study of Asthma and Allergies in Childhood (ISAAC). Nutrients, 2018, 10, 316.	1.7	44
112	Birth weight and subsequent body mass index in children: an international crossâ€sectional study. Pediatric Obesity, 2017, 12, 280-285.	1.4	13
113	β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. ERJ Open Research, 2017, 3, 00090-2016.	1.1	4
114	Longitudinal variation of serum periostin levels in adults with stable asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1687-1688.e9.	1.5	18
115	Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma. Allergy, Asthma and Clinical Immunology, 2017, 13, 8.	0.9	11
116	Effect of 0.9% Saline or Plasma-Lyte 148 as Crystalloid Fluid Therapy in the Intensive Care Unit on Blood Product Use and Postoperative Bleeding After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 1630-1638.	0.6	15
117	Physiological effects of titrated oxygen via nasal highâ€flow cannulae in <scp>COPD</scp> exacerbations: <scp>A</scp> randomized controlled crossâ€over trial. Respirology, 2017, 22, 1149-1155.	1.3	78
118	Adult asthma quick reference guides: <scp>T</scp> ransâ€ <scp>T</scp> asman differences in opinion. Respirology, 2017, 22, 9-11.	1.3	1
119	Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial. Npj Primary Care Respiratory Medicine, 2017, 27, 33.	1.1	10
120	Lower limb immobilisation and venous thromboembolism risk: combined case–control studies. Postgraduate Medical Journal, 2017, 93, 354-359.	0.9	14
121	RCT of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study. BMJ Open, 2017, 7, e013850.	0.8	3
122	Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma. BMJ Open Respiratory Research, 2017, 4, e000217.	1.2	15
123	Vitamin D and asthma: a case to answer. Lancet Respiratory Medicine,the, 2017, 5, 839-840.	5.2	0
124	Precision medicine in airway diseases: moving to clinical practice. European Respiratory Journal, 2017, 50, 1701655.	3.1	151
125	Protocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting. BMJ Open, 2017, 7, e017766.	0.8	9
126	Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012). Lancet, The, 2017, 390, 935-945.	6.3	209

#	Article	IF	CITATIONS
127	Phenotypes of symptomatic airways disease in China and New Zealand. European Respiratory Journal, 2017, 50, 1700957.	3.1	9
128	Target oxygen saturation range: 92–96% Versus 94–98%. Respirology, 2017, 22, 200-202.	1.3	26
129	Asthma prescribing: <scp>W</scp> here are we headed?. Respirology, 2017, 22, 1487-1488.	1.3	3
130	High flow or titrated oxygen for obese medical inpatients: a randomised crossover trial. Medical Journal of Australia, 2017, 207, 430-434.	0.8	10
131	Legflow® increases lower-limb venous haemodynamics when seated: A randomised controlled trial. Occupational Ergonomics, 2016, 12, 131-140.	0.3	0
132	Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study. Pulmonary Medicine, 2016, 2016, 1-7.	0.5	5
133	Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease. Clinical and Experimental Allergy, 2016, 46, 1303-1314.	1.4	37
134	Effect of smoking status on the efficacy of the SMART regimen in high risk asthma – Reply. Respirology, 2016, 21, 968-969.	1.3	0
135	Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. Respirology, 2016, 21, 858-866.	1.3	14
136	Randomised controlled trial of topical kanuka honey for the treatment of acne. BMJ Open, 2016, 6, e009448.	0.8	14
137	Validation of a metered dose inhaler electronic monitoring device: implications for asthma clinical trial use. BMJ Open Respiratory Research, 2016, 3, e000128.	1.2	23
138	Cohort feasibility study of an intermittent pneumatic compression device within a below-knee cast for the prevention of venous thromboembolism. BMJ Open, 2016, 6, e012764.	0.8	3
139	Acetaminophen for Fever in Critically Ill Patients with Suspected Infection. New England Journal of Medicine, 2016, 374, 1291-1293.	13.9	3
140	Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma. Respiratory Medicine, 2016, 119, 115-121.	1.3	12
141	Venous thromboembolism risk associated with protracted work- and computer-related seated immobility: A case-control study. JRSM Open, 2016, 7, 205427041663267.	0.2	22
142	Randomized controlled trial of the effect of regular paracetamol on influenza infection. Respirology, 2016, 21, 370-377.	1.3	16
143	Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. Journal of Thrombosis and Haemostasis, 2016, 14, 331-335.	1.9	10
144	Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. Human Vaccines and Immunotherapeutics, 2016, 12, 2197-2203.	1.4	22

#	Article	IF	CITATIONS
145	Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. European Respiratory Journal, 2016, 47, 981-984.	3.1	18
146	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	3.1	746
147	Serum periostin in obstructive airways disease. European Respiratory Journal, 2016, 47, 1383-1391.	3.1	43
148	Pilot study of feasibility of a randomised controlled trial of asthma risk with paracetamol versus ibuprofen use in infancy. New Zealand Medical Journal, 2016, 129, 30-42.	0.5	5
149	Asthma and Respiratory Foundation NZ adult asthma guidelines: a quick reference guide. New Zealand Medical Journal, 2016, 129, 83-102.	0.5	12
150	Association between paracetamol use in infancy or childhood with body mass index. Obesity, 2015, 23, 1030-1038.	1.5	5
151	<scp>T</scp> horacic <scp>S</scp> ociety of <scp>A</scp> ustralia and <scp>N</scp> ew <scp>Z</scp> ealand oxygen guidelines for acute oxygen use in adults: †Swimming between the flags'. Respirology, 2015, 20, 1182-1191.	1.3	139
152	The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis. Npj Primary Care Respiratory Medicine, 2015, 25, 14099.	1.1	34
153	Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use. BMJ Open Respiratory Research, 2015, 2, e000097.	1.2	38
154	Maternal post-natal tobacco use and current parental tobacco use is associated with higher body mass index in children and adolescents: an international cross-sectional study. BMC Pediatrics, 2015, 15, 220.	0.7	11
155	Acute use of oxygen therapy. Australian Prescriber, 2015, 38, 98-100.	0.5	14
156	Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2015, 9, 287-293.	1.0	17
157	Randomised controlled trial of topical kanuka honey for the treatment of rosacea. BMJ Open, 2015, 5, e007651.	0.8	24
158	Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial. BMJ Open, 2015, 5, e006131-e006131.	0.8	21
159	Early temperature and mortality in critically ill patients with acute neurological diseases: trauma and stroke differ from infection. Intensive Care Medicine, 2015, 41, 823-832.	3.9	106
160	Comparative audit of oxygen use in the prehospital setting in acute COPD exacerbation over 5â€years. Emergency Medicine Journal, 2015, 32, 234-238.	0.4	12
161	Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. Journal of Allergy and Clinical Immunology, 2015, 136, 601-609.	1.5	41
162	The association between paracetamol use and asthma: causation or coincidence?. Clinical and Experimental Allergy, 2015, 45, 108-113.	1.4	17

#	Article	IF	CITATIONS
163	The effect of 1g of acetaminophen twice daily for 12weeks on alanine transaminase levels—A randomized placebo-controlled trial. Clinical Biochemistry, 2015, 48, 713-715.	0.8	5
164	Randomized controlled trial of asthma risk with paracetamol use in infancy – a feasibility study. Clinical and Experimental Allergy, 2015, 45, 448-456.	1.4	10
165	Acetaminophen for Fever in Critically III Patients with Suspected Infection. New England Journal of Medicine, 2015, 373, 2215-2224.	13.9	183
166	Cohort study of a simple â€~Step-Up' regimen with the Asthma Control Test. Respirology, 2015, 20, 504-506.	1.3	2
167	Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2015, 314, 1701.	3.8	582
168	Risk factors for asthma: is prevention possible?. Lancet, The, 2015, 386, 1075-1085.	6.3	390
169	Upper extremity deep vein thrombosis in a TV cameraman. Occupational Medicine, 2015, 65, 337-339.	0.8	7
170	Association between breastfeeding and body mass index at age 6–7 years in an international survey. Pediatric Obesity, 2015, 10, 283-287.	1.4	23
171	Association between early peak temperature and mortality in neutropenic sepsis. Annals of Hematology, 2015, 94, 857-864.	0.8	10
172	Randomised placebo-controlled study of the effect of paracetamol on asthma severity in adults. BMJ Open, 2014, 4, e004324.	0.8	10
173	A randomised controlled trial of topical Kanuka honey for the treatment of eczema. JRSM Open, 2014, 5, 204253331350926.	0.2	2
174	A randomised controlled trial of topical Kanuka honey for the treatment of psoriasis. JRSM Open, 2014, 5, 204253331351891.	0.2	8
175	A man who collapsed after using the internet. JRSM Open, 2014, 5, 205427041454339.	0.2	5
176	Combination budesonide/formoterol inhaler as maintenance and reliever therapy in <scp>M</scp> Äori with asthma. Respirology, 2014, 19, 842-851.	1.3	17
177	Birthweight and the risk of atopic diseases: the ISAAC Phase III study. Pediatric Allergy and Immunology, 2014, 25, 264-270.	1.1	17
178	Occupational Risk Factors for Chronic Respiratory Disease in a New Zealand Population Using Lifetime Occupational History. Journal of Occupational and Environmental Medicine, 2014, 56, 270-280.	0.9	18
179	Letter in response to Tashkinet al: limited generalisability of uplift findings to clinical practice. Thorax, 2014, 69, 385.2-386.	2.7	0
180	Combination corticosteroid/l²-agonist inhaler as reliever therapy: A solution for intermittent and mild asthma?. Journal of Allergy and Clinical Immunology, 2014, 133, 39-41.	1.5	55

#	Article	IF	CITATIONS
181	Topical kanuka honey for the treatment of nappy rash. Focus on Alternative and Complementary Therapies, 2014, 19, 50-51.	0.1	1
182	Predictors of Severe Exacerbations, Poor Asthma Control, and β-Agonist Overuse for Patients with Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 751-758.e1.	2.0	56
183	HyperOxic Therapy OR NormOxic Therapy after out-of-hospital cardiac arrest (HOT OR NOT): A randomised controlled feasibility trial. Resuscitation, 2014, 85, 1686-1691.	1.3	84
184	Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. International Journal of Obesity, 2014, 38, 1115-1119.	1.6	141
185	Fast-food consumption and body mass index in children and adolescents: an international cross-sectional study. BMJ Open, 2014, 4, e005813.	0.8	118
186	Use of Metered-Dose Inhaler Electronic Monitoring in a Real-World Asthma Randomized Controlled Trial. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 83-91.	2.0	62
187	The effect of high concentration oxygen therapy on PaCO2 in acute and chronic respiratory disorders. Translational Respiratory Medicine, 2013, 1, 8.	3.8	9
188	A half doubling dose change in bronchial hyperresponsiveness in a population represents an important difference. Translational Respiratory Medicine, 2013, 1, 4.	3.8	4
189	Short-Acting β-Agonist Use As a Marker of Current Asthma Control. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 370-377.	2.0	20
190	Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax, 2013, 68, 338-343.	2.7	16
191	The association between SpO2 values and mortality – Interpret with caution. Resuscitation, 2013, 84, e41.	1.3	0
192	Delivery of titrated oxygen via a self-inflating resuscitation bag. Resuscitation, 2013, 84, 391-394.	1.3	21
193	Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respiratory Medicine,the, 2013, 1, 32-42.	5.2	157
194	The association between <scp>BMI</scp> , vigorous physical activity and television viewing and the risk of symptoms of asthma, rhinoconjunctivitis and eczema in children and adolescents: <scp>ISAAC</scp> Phase Three. Clinical and Experimental Allergy, 2013, 43, 73-84.	1.4	110
195	Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression ofÂChurg-Strauss syndrome. Journal of Allergy and Clinical Immunology, 2013, 131, 571-576.e6.	1.5	63
196	Tiotropium Respimat increases the risk of mortality: pro. European Respiratory Journal, 2013, 42, 584-589.	3.1	13
197	Restriction of LABA use to combination ICS/LABA inhaler therapy in asthma. Thorax, 2013, 68, 119-120.	2.7	7
198	The β-2 agonist debate. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 58-62.	1.1	2

#	Article	IF	CITATIONS
199	Authors' response to Metzdorfet al. Thorax, 2013, 68, 782.2-783.	2.7	1
200	Authors' reply to †Explaining differential effects of tiotropium on mortality in COPD'. Thorax, 2013, 68, 590-591.	2.7	1
201	Efficacy of Micromobile Foot Compression Device in Increasing Lower Limb Venous Blood Flow. International Journal of Vascular Medicine, 2013, 2013, 1-6.	0.4	10
202	Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clinical and Experimental Allergy, 2013, 43, 1144-1151.	1.4	61
203	Accuracy of patient selfâ€report as a measure of inhaled asthma medication use. Respirology, 2013, 18, 546-552.	1.3	60
204	Topical kanuka honey for the treatment of rosacea. Focus on Alternative and Complementary Therapies, 2013, 18, 221-222.	0.1	4
205	Limited generalisability of UPLIFT findings to clinical practice: TableÂ1. Thorax, 2013, 68, 1066-1067.	2.7	23
206	Combination ICS/fast-onset LABA inhaler as maintenance and reliever therapy: the future for uncontrolled adult asthma?. Expert Review of Respiratory Medicine, 2013, 7, 451-454.	1.0	6
207	Tiotropium Respimat increases the risk of mortality. Thorax, 2013, 68, 5-7.	2.7	25
208	The Worldwide Association between Television Viewing and Obesity in Children and Adolescents: Cross Sectional Study. PLoS ONE, 2013, 8, e74263.	1.1	78
209	Bronchodilator responsiveness: interpret with caution. Thorax, 2012, 67, 667-668.	2.7	16
210	British National Formulary for Children: the risk of inappropriate paracetamol prescribing. Archives of Disease in Childhood, 2012, 97, 279-282.	1.0	13
211	The risk of serious adverse outcomes associated with hypoxaemia and hyperoxaemia in acute exacerbations of COPD. Postgraduate Medical Journal, 2012, 88, 684-689.	0.9	61
212	The association between tobacco and the risk of asthma, rhinoconjunctivitis and eczema in children and adolescents: analyses from Phase Three of the ISAAC programme. Thorax, 2012, 67, 941-949.	2.7	104
213	Systematic review and meta-analysis of the effects of antipyretic medications on mortality in <i>Streptococcus pneumoniae</i> infections. Postgraduate Medical Journal, 2012, 88, 21-27.	0.9	11
214	Towards individualised medicine for airways disease: identifying clinical phenotype groups: Figure 1–. European Respiratory Journal, 2012, 39, 1033-1034.	3.1	5
215	Randomized controlled trial of high concentration oxygen in suspected community-acquired pneumonia. Journal of the Royal Society of Medicine, 2012, 105, 208-216.	1.1	35
216	Remote ischaemic preconditioning does not alter perioperative cytokine production in high-risk cardiac surgery. Heart Asia, 2012, 4, 97-101.	1.1	6

#	Article	IF	CITATIONS
217	Proposed MHRA changes to UK children's paracetamol dosing recommendations: modelling study. Journal of the Royal Society of Medicine, 2012, 105, 263-269.	1.1	5
218	Authors' response: hyperoxia in acute asthma. Thorax, 2012, 67, 834.1-834.	2.7	0
219	Randomised controlled crossover trial of the effect on Ptco2of oxygen-driven versus air-driven nebulisers in severe chronic obstructive pulmonary disease. Emergency Medicine Journal, 2012, 29, 894-898.	0.4	21
220	Understanding the true burden of COPD: the epidemiological challenges. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 249-251.	2.5	31
221	The challenges of replicating the methodology between Phases I and III of the ISAAC programme. International Journal of Tuberculosis and Lung Disease, 2012, 16, 687-693.	0.6	11
222	Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ, The, 2012, 345, e7390-e7390.	3.0	24
223	A systematic review and meta-analysis of the cardioprotective effects of remote ischaemic preconditioning in open cardiac surgery. Journal of the Royal Society of Medicine, 2012, 105, 436-445.	1.1	49
224	The Global Lung Initiative 2012 reference values reflect contemporary Australasian spirometry. Respirology, 2012, 17, 1150-1151.	1.3	87
225	Pandemic Influenza A(H1N1)2009 in Hospital Healthcare Workers in New Zealand. Infection Control and Hospital Epidemiology, 2012, 33, 196-199.	1.0	3
226	The effect of hyperoxia following cardiac arrest – A systematic review and meta-analysis of animal trials. Resuscitation, 2012, 83, 417-422.	1.3	143
227	High-concentration versus titrated oxygen therapy in ST-elevation myocardial infarction: A pilot randomized controlled trial. American Heart Journal, 2012, 163, 168-175.	1.2	73
228	A randomised controlled trial of the effect of high concentration oxygen on myocardial ischaemia during exercise. International Journal of Cardiology, 2012, 160, 201-205.	0.8	6
229	Six-month inÂvitro validation of a metered-dose inhaler electronic monitoring device: Implications for asthma clinical trial use. Journal of Allergy and Clinical Immunology, 2012, 130, 1420-1422.	1.5	33
230	Inhaled magnesium sulfate in the treatment of acute asthma. The Cochrane Library, 2012, 12, CD003898.	1.5	35
231	A pilot study investigating the effects of remote ischemic preconditioning in high-risk cardiac surgery using a randomised controlled double-blind protocol. Basic Research in Cardiology, 2012, 107, 256.	2.5	103
232	Tuberculosis, bacillus Calmette–Guérin vaccination, and allergic disease: Findings from the International Study of Asthma and Allergies in Childhood Phase Two. Pediatric Allergy and Immunology, 2012, 23, 324-331.	1.1	24
233	Childhood asthma and GOLDâ€defined chronic obstructive pulmonary disease. Internal Medicine Journal, 2012, 42, 83-88.	0.5	44
234	How to write research papers and grants: 2011 Asian Pacific Society for Respirology Annual Scientific Meeting Postgraduate Session. Respirology, 2012, 17, 792-801.	1.3	3

#	Article	IF	CITATIONS
235	Arterial oxygen tension and mortality in mechanically ventilated patients. Intensive Care Medicine, 2012, 38, 91-98.	3.9	159
236	Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Medicine, 2012, 38, 437-444.	3.9	173
237	The HEAT trial: a protocol for a multicentre randomised placebo-controlled trial of IV paracetamol in ICU patients with fever and infection. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2012, 14, 290-6.	0.0	11
238	Supplementary oxygen for nonhypoxemic patients: O2 much of a good thing?. Critical Care, 2011, 15, 305.	2.5	47
239	Acetaminophen Use and Risk of Asthma, Rhinoconjunctivitis, and Eczema in Adolescents. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 171-178.	2.5	122
240	Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax, 2011, 66, 937-941.	2.7	96
241	Clobal analysis of breast feeding and risk of symptoms of asthma, rhinoconjunctivitis and eczema in 6–7 year old children: ISAAC Phase Three. Allergologia Et Immunopathologia, 2011, 39, 318-325.	1.0	37
242	Incidental findings from lung CT scans: Implications for research. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 20-25.	0.9	6
243	High-concentration oxygen therapy in COPD. Lancet, The, 2011, 378, 969-970.	6.3	24
244	Fever and antipyresis in infection. Medical Journal of Australia, 2011, 195, 458-459.	0.8	9
245	Acetaminophen and Asthma: Spurious Association?. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1570-1571.	2.5	2
246	The multiple dimensions of airways disease: targeting treatment to clinical phenotypes. Current Opinion in Pulmonary Medicine, 2011, 17, 72-78.	1.2	28
247	A hypothesis to phenotype COPD exacerbations by aetiology. Respirology, 2011, 16, 264-268.	1.3	15
248	The value of the CRB65 score to predict mortality in exacerbations of COPD requiring hospital admission. Respirology, 2011, 16, 625-629.	1.3	29
249	The allâ€age spirometry reference ranges reflect contemporary Australasian spirometry. Respirology, 2011, 16, 912-917.	1.3	39
250	Preâ€hospital oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Internal Medicine Journal, 2011, 41, 618-622.	0.5	65
251	Assessing PaCO <sub>2</sub> in acute respiratory disease: accuracy of a transcutaneous carbon dioxide device. Internal Medicine Journal, 2011, 41, 630-633.	0.5	21
252	The effects of early and late paracetamol exposure on asthma and atopy: a birth cohort. Clinical and Experimental Allergy, 2011, 41, 399-406.	1.4	60

#	Article	IF	CITATIONS
253	Paracetamol in pregnancy and the risk of wheezing in offspring: a systematic review and metaâ€analysis. Clinical and Experimental Allergy, 2011, 41, 482-489.	1.4	96
254	Merino wool graduated compression stocking increases lower limb venous blood flow: A randomized controlled trial. Advances in Therapy, 2011, 28, 227-237.	1.3	22
255	Towards individualised treatment in COPD. Thorax, 2011, 66, 363-364.	2.7	16
256	The Effect of Supplemental Oxygen on Hypercapnia in Subjects With Obesity-Associated Hypoventilation. Chest, 2011, 139, 1018-1024.	0.4	106
257	Fever and fever management among intensive care patients with known or suspected infection: a multicentre prospective cohort study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2011, 13, 97-102.	0.0	12
258	The role of paracetamol in the pathogenesis of asthma. Clinical and Experimental Allergy, 2010, 40, 32-41.	1.4	68
259	Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma. Allergy and Asthma Proceedings, 2010, 31, 415-421.	1.0	19
260	Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. Respiratory Research, 2010, 11, 8.	1.4	100
261	Programming in asthma: the dice are loaded but not cast. Clinical and Experimental Allergy, 2010, 40, 1717-1718.	1.4	0
262	Asthma: Time to confront some inconvenient truths. Respirology, 2010, 15, 194-201.	1.3	20
263	Venous thromboembolism following prolonged cast immobilisation for injury to the tendo Achillis. Journal of Bone and Joint Surgery: British Volume, 2010, 92-B, 646-650.	3.4	74
264	Effect of diet on asthma and allergic sensitisation in the International Study on Allergies and Asthma in Childhood (ISAAC) Phase Two. Thorax, 2010, 65, 516-522.	2.7	193
265	Use of cluster analysis to define COPD phenotypes. European Respiratory Journal, 2010, 36, 472-474.	3.1	64
266	Randomised double-blind, placebo-controlled trial of the effects of the â€~party pills' BZP/TFMPP alone and in combination with alcohol. Journal of Psychopharmacology, 2010, 24, 1299-1308.	2.0	73
267	Prolonged work- and computer-related seated immobility and risk of venous thromboembolism. Journal of the Royal Society of Medicine, 2010, 103, 447-454.	1.1	68
268	The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analyis. Journal of the Royal Society of Medicine, 2010, 103, 403-411.	1.1	70
269	Ambient particulate pollution and the world-wide prevalence of asthma, rhinoconjunctivitis and eczema in children: Phase One of the International Study of Asthma and Allergies in Childhood (ISAAC). Occupational and Environmental Medicine, 2010, 67, 293-300.	1.3	76
270	Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax, 2010, 65, 132-138.	2.7	83

#	Article	IF	CITATIONS
271	Long-Acting Beta-Agonists and Asthma Death: How Useful Are Different Study Designs to Evaluate the Potential Association?. Journal of Asthma, 2010, 47, 434-438.	0.9	7
272	From the authors:. European Respiratory Journal, 2010, 35, 459-460.	3.1	1
273	Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax, 2010, 65, 39-43.	2.7	104
274	Avoidance of high concentration oxygen in chronic obstructive pulmonary disease. BMJ: British Medical Journal, 2010, 341, c5549-c5549.	2.4	7
275	Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting β-agonist inhaler therapy in asthma. Journal of Allergy and Clinical Immunology, 2010, 126, 505-510.	1.5	32
276	An audit of the effect of oxygen prescription charts on clinical practice. Postgraduate Medical Journal, 2010, 86, 89-93.	0.9	22
277	Call for withdrawal of LABA single-therapy inhaler in asthma. Lancet, The, 2010, 376, 750-751.	6.3	30
278	Risk Factors and Immunity in a Nationally Representative Population following the 2009 Influenza A(H1N1) Pandemic. PLoS ONE, 2010, 5, e13211.	1.1	90
279	Effect of sitting in ergonomic chairs on lower limb venous blood flow. Occupational Ergonomics, 2009, 8, 125-132.	0.3	8
280	Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax, 2009, 64, 476-483.	2.7	806
281	Distinct clinical phenotypes of airways disease defined by cluster analysis. European Respiratory Journal, 2009, 34, 812-818.	3.1	206
282	Review: Should ethanol be scheduled as a drug of high risk to public health?. Journal of Psychopharmacology, 2009, 23, 94-100.	2.0	6
283	Safety of long-acting Â-agonists: urgent need to clear the air remains. European Respiratory Journal, 2009, 33, 3-5.	3.1	42
284	Potential Risks of Using LABAs with ICS Therapy. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 581-581.	2.5	1
285	Quality of life measured by the St George's Respiratory Questionnaire and spirometry. European Respiratory Journal, 2009, 33, 1025-1030.	3.1	53
286	Risk of mortality associated with formoterol: a systematic review and meta-analysis. European Respiratory Journal, 2009, 34, 803-811.	3.1	32
287	Dose–response relationship of inhaled corticosteroids and cataracts: A systematic review and metaâ€analysis. Respirology, 2009, 14, 983-990.	1.3	83
288	Frequency of dosing and comparative doses of mometasone furoate: A metaâ€analysis. Respirology, 2009, 14, 1166-1172.	1.3	4

#	Article	IF	CITATIONS
289	Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 123-148.	2.7	338
290	Systematic review of studies of the effect of hyperoxia on coronary blood flow. American Heart Journal, 2009, 158, 371-377.	1.2	220
291	The acetaminophen and asthma hypothesis 10 years on: A case to answer. Journal of Allergy and Clinical Immunology, 2009, 124, 649-651.	1.5	30
292	Paracetamol as a risk factor for allergic disorders – Authors' reply. Lancet, The, 2009, 373, 120-121.	6.3	6
293	Time to define the disorders of the syndrome of COPD. Lancet, The, 2009, 374, 670-672.	6.3	44
294	International Trends in Asthma Mortality Rates in the 5- to 34-Year Age Group. Chest, 2009, 135, 1045-1049.	0.4	48
295	Epidemiology of Asthma Mortality. , 2009, , 107-122.		7
296	INTRODUCTION: Avian influenza: From basic biology to pandemic planning. Respirology, 2008, 13, S1-S1.	1.3	1
297	Prolonged seated immobility at work is a common risk factor for venous thromboembolism leading to hospital admission. Internal Medicine Journal, 2008, 38, 133-135.	0.5	34
298	Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatric Allergy and Immunology, 2008, 19, 110-124.	1.1	321
299	Dose–response relationship for risk of nonâ€vertebral fracture with inhaled corticosteroids. Clinical and Experimental Allergy, 2008, 38, 1451-1458.	1.4	72
300	Cannabis use and cancer of the head and neck: Case ontrol study. Otolaryngology - Head and Neck Surgery, 2008, 138, 374-380.	1.1	57
301	Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from Phase Three of the ISAAC programme. Lancet, The, 2008, 372, 1039-1048.	6.3	349
302	Cannabis use and risk of lung cancer: a case-control study. European Respiratory Journal, 2008, 31, 280-286.	3.1	214
303	The New Zealand national junior doctors' strike: implications for the provision of acute hospital medical services. Clinical Medicine, 2008, 8, 272-275.	0.8	22
304	Routine use of oxygen in the treatment of myocardial infarction: systematic review. Heart, 2008, 95, 198-202.	1.2	144
305	High effectiveness of short treatment with bupropion for smoking cessation in general care. Thorax, 2008, 63, 476-477.	2.7	4
306	Proportional classifications of COPD phenotypes. Thorax, 2008, 63, 761-767.	2.7	192

#	Article	IF	CITATIONS
307	A case–control study of seated immobility at work as a risk factor for venous thromboembolism. Journal of the Royal Society of Medicine, 2008, 101, 237-243.	1.1	35
308	The risk of asthma mortality with inhaled long acting Â-agonists. Postgraduate Medical Journal, 2008, 84, 467-472.	0.9	29
309	Leukotriene receptor antagonist therapy and Churg-Strauss syndrome: culprit or innocent bystander?. Thorax, 2008, 63, 847-849.	2.7	25
310	COPD prevalence in a random population survey: a matter of definition. European Respiratory Journal, 2007, 30, 232-239.	3.1	113
311	Asthma exacerbations {middle dot} 5: Assessment and management of severe asthma in adults in hospital. Thorax, 2007, 62, 447-458.	2.7	36
312	Oxygen therapy in myocardial infarction: an historical perspective. Journal of the Royal Society of Medicine, 2007, 100, 130-133.	1.1	34
313	Reference Ranges for Exhaled Nitric Oxide Derived from a Random Community Survey of Adults. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 238-242.	2.5	196
314	Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax, 2007, 62, 758-766.	2.7	988
315	Effects of cannabis on pulmonary structure, function and symptoms. Thorax, 2007, 62, 1058-1063.	2.7	259
316	External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?. Thorax, 2007, 62, 219-223.	2.7	250
317	Is it time to change the approach to oxygen therapy in the breathless patient?. Thorax, 2007, 62, 840-841.	2.7	25
318	Oxygen therapy in myocardial infarction: an historical perspective. Journal of the Royal Society of Medicine, 2007, 100, 130-133.	1.1	45
319	Magnesium in the treatment of asthma. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 107-110.	1.1	11
320	External validity of randomized controlled trials in COPD. Respiratory Medicine, 2007, 101, 1313-1320.	1.3	126
321	Utility of lung density measurements in the diagnosis of emphysema. Respiratory Medicine, 2007, 101, 1512-1520.	1.3	42
322	Balancing the Risks and Benefits of Celecoxib. American Journal of Medicine, 2007, 120, e17.	0.6	0
323	Atopic Sensitization and the International Variation of Asthma Symptom Prevalence in Children. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 565-574.	2.5	290
324	Poppy seed tea and opiate abuse in New Zealand. Drug and Alcohol Review, 2007, 26, 215-219.	1.1	34

#	Article	IF	CITATIONS
325	An audiovisual reminder function improves adherence with inhaled corticosteroid therapyÂin asthma. Journal of Allergy and Clinical Immunology, 2007, 119, 811-816.	1.5	144
326	Hemochromatosis gene mutations, liver function tests and iron status in alcohol-dependent patients admitted for detoxification. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 852-854.	1.4	5
327	Respirology year-in-review 2006: Clinical science. Respirology, 2007, 12, 6-15.	1.3	1
328	Pulmonary function testing in New Zealand: The use and importance of reference ranges. Respirology, 2007, 12, 367-374.	1.3	6
329	Unmet need in inadequately controlled asthma. Respirology, 2007, 12, S18-S21.	1.3	9
330	New look at the oxyhaemoglobin dissociation curve. Lancet, The, 2006, 367, 1124-1126.	6.3	28
331	A historical perspective of the New Zealand asthma mortality epidemics. Journal of Allergy and Clinical Immunology, 2006, 117, 225-228.	1.5	15
332	Epidemiology and costs of chronic obstructive pulmonary disease. European Respiratory Journal, 2006, 27, 188-207.	3.1	606
333	The 24h duration of bronchodilator action of the budesonide/formoterol combination inhaler. Respiratory Medicine, 2006, 100, 20-25.	1.3	15
334	Recent air travel and venous thromboembolism resulting in hospital admission. Respirology, 2006, 11, 75-79.	1.3	12
335	A year in review: Respirology 2005 - Clinical science. Respirology, 2006, 11, 124-130.	1.3	2
336	Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: A randomized controlled trial in childhood asthma. Respirology, 2006, 11, 638-642.	1.3	8
337	Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. Journal of the Royal Society of Medicine, 2006, 99, 132-140.	1.1	155
338	Inconsistencies in cardiovascular data from COX-2 inhibitor trialsis it a class effect?. Journal of the Royal Society of Medicine, 2006, 99, 275-276.	1.1	4
339	Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. European Respiratory Journal, 2006, 28, 960-967.	3.1	46
340	Smoking and COPD: what really are the risks?. European Respiratory Journal, 2006, 28, 883-884.	3.1	50
341	Physiological associations of computerized tomography lung density: a factor analysis. International Journal of COPD, 2006, 1, 181-187.	0.9	14
342	Complete reference ranges for pulmonary function tests from a single New Zealand population. New Zealand Medical Journal, 2006, 119, U2281.	0.5	13

#	Article	IF	CITATIONS
343	Aerosolized Magnesium Sulfate for Acute Asthma. Chest, 2005, 128, 337-344.	0.4	78
344	Determinants of plasma D-dimer levels in a traveling population. Journal of Thrombosis and Haemostasis, 2005, 3, 2445-2448.	1.9	14
345	Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 309-316.	2.7	998
346	Metered dose inhalers: A need for dose counters. Respirology, 2005, 10, 105-106.	1.3	14
347	Fluticasone given once versus twice a day: Meta-analysis. Respirology, 2005, 10, 183-188.	1.3	18
348	Fixed and adjustable dose asthma action plans based on combination therapy: A pilot study. Respirology, 2005, 10, 497-503.	1.3	8
349	Venous Thromboembolism in Medical Inpatients–-the Silent Epidemic of Neglect. Journal of the Royal Society of Medicine, 2005, 98, 484-485.	1.1	1
350	Efficacy of bupropion in the indigenous Maori population in New Zealand. Thorax, 2005, 60, 120-123.	2.7	36
351	Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax, 2005, 60, 730-734.	2.7	102
352	Optimal starting dose of inhaled corticosteroids in adult asthma: why has it taken so long?. Thorax, 2005, 60, 93-94.	2.7	3
353	Venous thromboembolism in medical inpatientsthe silent epidemic of neglect. Journal of the Royal Society of Medicine, 2005, 98, 484-485.	1.1	2
354	Letter to the editor. Clinical Therapeutics, 2005, 27, 355-357.	1.1	4
355	Seasonal Variation in Asthma-Related Hospital and Intensive Care Unit Admissions. Journal of Asthma, 2005, 42, 265-271.	0.9	42
356	The 24h duration of bronchodilator action of the salmeterol/fluticasone combination inhaler. Respiratory Medicine, 2005, 99, 545-552.	1.3	16
357	SIT (seated immobility thromboembolism) syndrome: a 21st century lifestyle hazard. New Zealand Medical Journal, 2005, 118, U1376.	0.5	10
358	Systematic review of the dose-response relation of inhaled fluticasone propionate. Archives of Disease in Childhood, 2004, 89, 902-907.	1.0	40
359	Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. European Respiratory Journal, 2004, 23, 552-558.	3.1	90
360	The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 469-478.	2.7	2,850

#	Article	IF	CITATIONS
361	The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: A comparison with salbutamol. Respirology, 2004, 9, 102-108.	1.3	20
362	What is the 'appropriate' term for saline nose drops: Placebo or drug?. Respirology, 2004, 9, 423-423.	1.3	1
363	Budesonide once versus twice-daily administration: meta-analysis. Respirology, 2004, 9, 528-534.	1.3	29
364	Effect of repeated intradermal injections of heat-inactivated Mycobacterium bovis bacillus Calmette-Guerin in adult asthma. Clinical and Experimental Allergy, 2004, 34, 207-212.	1.4	38
365	The dose-response relationship of inhaled corticosteroids in asthma. Current Allergy and Asthma Reports, 2004, 4, 144-148.	2.4	12
366	The use of the self-management plan system of care in adult asthma. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2004, 13, 19-27.	2.5	25
367	Increasing compliance with inhaled corticosteroids through the use of combination therapy. Journal of Allergy and Clinical Immunology, 2004, 113, 219-220.	1.5	11
368	Rates and characteristics of intensive care unit admissions and intubations among asthma-related hospitalizations. Annals of Allergy, Asthma and Immunology, 2004, 93, 29-35.	0.5	106
369	Asthma exacerbations and inhaled corticosteroids. Lancet, The, 2004, 363, 1236.	6.3	3
370	Association of asthma therapy and churg-strauss syndrome: An analysis of postmarketing surveillance data. Clinical Therapeutics, 2004, 26, 1092-1104.	1.1	62
371	Diagnosis and management of adult asthma. Medicine, 2003, 31, 63-68.	0.2	0
372	Rhinovirus is not detectable in peripheral lung tissue after asthma death. Respirology, 2003, 8, 234-238.	1.3	7
373	Pilot study of the safety and effect of intranasal delipidated acid-treated Mycobacterium vaccae in adult asthma. Respirology, 2003, 8, 497-503.	1.3	14
374	What to do at step 3 of the asthma guidelines—increase the dose of inhaled corticosteroids or add a long-acting β-agonist drug?. Journal of Allergy and Clinical Immunology, 2003, 112, 10-11.	1.5	7
375	International patterns of the prevalence of pediatric asthma. Pediatric Clinics of North America, 2003, 50, 539-553.	0.9	88
376	Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Lancet, The, 2003, 361, 2114-2117.	6.3	85
377	Nebulised salbutamol and magnesium sulphate in acute asthma. Lancet, The, 2003, 362, 1079.	6.3	0
378	Frequency of venous thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Traveller's Thrombosis (NZATT) study. Lancet, The, 2003, 362, 2039-2044.	6.3	133

#	Article	IF	CITATIONS
379	Humidified nasal continuous positive airway pressure in obstructive sleep apnoea. European Respiratory Journal, 2003, 22, 258-262.	3.1	86
380	eThrombosis: the 21st Century variant of venous thromboembolism associated with immobility. European Respiratory Journal, 2003, 21, 374-376.	3.1	95
381	One name to rule them all, one name to find them: Lord of the Rings and 'seated immobility thromboembolism (SIT) syndrome'. New Zealand Medical Journal, 2003, 116, U498.	0.5	3
382	The burden of asthma with specific reference to the United States. Journal of Allergy and Clinical Immunology, 2002, 109, S482-S489.	1.5	160
383	Asthma and allergy: a worldwide problem of meanings and management?. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 663-672.	2.7	20
384	Mycobacterium-based vaccines for the prevention of allergic disease: a progress report. Clinical and Experimental Allergy, 2002, 32, 1128-1130.	1.4	10
385	Airway remodelling in asthma. Clinical and Experimental Allergy Reviews, 2002, 2, 109-116.	0.3	17
386	An inverse correlation between estimated tuberculosis notification rates and asthma symptoms. Respirology, 2002, 7, 153-155.	1.3	37
387	The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction. Respirology, 2002, 7, 333-337.	1.3	50
388	Sleep disorders: a potential role in New Zealand motor vehicle accidents. Internal Medicine Journal, 2002, 32, 297-304.	0.5	25
389	Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. Journal of Allergy and Clinical Immunology, 2001, 107, 222-223.	1.5	19
390	Comparative studies of inhaled corticosteroids in asthma. European Respiratory Journal, 2001, 17, 579-580.	3.1	16
391	Head circumference at birth and the development of allergic disease - more questions than answers. Clinical and Experimental Allergy, 2001, 31, 1804-1805.	1.4	2
392	Asthma mortality in Japan: What can be done to bring the rate down?. Allergology International, 2001, 50, 265-272.	1.4	3
393	Has the role of atopy in the development of asthma been over-emphasized?. Pediatric Pulmonology, 2001, 26, 149-150.	1.0	11
394	Has the role of atopy in the development of asthma been over-emphasized?. Pediatric Pulmonology, 2001, 32, 149-150.	1.0	7
395	Reducing Asthma Mortality with the Asthma Self-Management Plan System of Care. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 3-4.	2.5	14
396	The Effect of Delipidated Deglycolipidated (DDMV) and Heat-killedMycobacterium vaccaein Asthma. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1410-1414.	2.5	61

#	Article	IF	CITATIONS
397	Asthma morbidity 6 yrs after an effective asthma self-management programme in a Maori community. European Respiratory Journal, 2000, 15, 464-469.	3.1	20
398	Seasonal variation in asthma hospitalizations and death rates in New Zealand. Respirology, 2000, 5, 241-246.	1.3	38
399	Association of β2 -adrenergic receptor polymorphisms with severe asthma. Clinical and Experimental Allergy, 2000, 30, 1097-1103.	1.4	111
400	Is allergen exposure the major primary cause of asthma?. Thorax, 2000, 55, 424-431.	2.7	174
401	International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema. Thorax, 2000, 55, 449-453.	2.7	173
402	Prevalence and etiology of asthma. Journal of Allergy and Clinical Immunology, 2000, 105, S466-S472.	1.5	395
403	Analysis of Two IL-4 Promoter Polymorphisms in a Cohort of Atopic and Asthmatic Subjects. Experimental and Clinical Immunogenetics, 1999, 16, 33-35.	1.4	9
404	Is Enhanced Fetal Growth a Risk Factor for the Development of Atopy or Asthma?. International Archives of Allergy and Immunology, 1999, 118, 408-410.	0.9	18
405	Preservatives in Nebulizer Solutions: Risks without Benefit–A Further Comment. Pharmacotherapy, 1999, 19, 473-474.	1.2	8
406	β agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality?â~†â~†â~†â. Journal of Allergy and Clinical Immunology, 1999, 104, S18-S30.	1.5	104
407	The magnitude of the effect of smaller family sizes on the increase in the prevalence of asthma and hay fever in the United Kingdom and New Zealand. Journal of Allergy and Clinical Immunology, 1999, 104, 554-558.	1.5	54
408	Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. Journal of Allergy and Clinical Immunology, 1999, 103, 125-138.	1.5	831
409	β-agonist therapy and asthma mortality in Japan. Lancet, The, 1998, 351, 1406-1407.	6.3	21
410	Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet, The, 1998, 351, 1225-1232.	6.3	3,158
411	Is Infant Immunization a Risk Factor for Childhood Asthma or Allergy?. Epidemiology, 1997, 8, 678-680.	1.2	66
412	RE: "CONFOUNDING BY INDICATION AND CHANNELING OVER TIME: THE RISKS OF Â2-AGONISTS". American Journal of Epidemiology, 1997, 146, 885-886.	1.6	9
413	Is Infant Immunization a Risk Factor for Childhood Asthma or Allergy?. Epidemiology, 1997, 8, 678.	1.2	130
414	Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatric Allergy and Immunology, 1997, 8, 161-168.	1.1	513

#	Article	IF	CITATIONS
415	The asthma self-management plan system of care. Patient Education and Counseling, 1997, 32, S21-S33.	1.0	22
416	International Trends in Asthma Mortality. Novartis Foundation Symposium, 1997, 206, 140-159.	1.2	12
417	ISOPRENALINE, FENOTEROL AND ASTHMA DEATHS IN JAPAN. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 1997, 11, 307-316.	0.0	3
418	Trial of a "credit card―asthma self-management plan in a high-risk group of patients with asthma. Journal of Allergy and Clinical Immunology, 1996, 97, 1085-1092.	1.5	37
419	Partial vs Full β-Receptor Agonism. Chest, 1996, 109, 957-962.	0.4	40
420	Problems of measuring asthma prevalence. Respirology, 1996, 1, 183-188.	1.3	26
421	The New Zealand Asthma Mortality Epidemic. Clinical Science, 1995, 88, 14-17.	1.8	5
422	Measuring the Prevalence of Bronchial Hyper-Responsiveness in Children. International Journal of Epidemiology, 1995, 24, 597-602.	0.9	82
423	An Approach to the Management of High Risk Asthmatic Patients. BioDrugs, 1995, 4, 445-450.	0.7	0
424	End of New Zealand asthma epidemic. Lancet, The, 1995, 345, 984-985.	6.3	7
425	End of the New Zealand asthma mortality epidemic. Lancet, The, 1995, 345, 41-44.	6.3	168
426	The effect of hypercapnia and hypoxemia on the cardiovascular responses to isoproterenol. Clinical Pharmacology and Therapeutics, 1994, 56, 302-308.	2.3	10
427	Methotrexate in Asthma. Drug Safety, 1993, 9, 151-155.	1.4	11
428	Markers of Risk of Asthma Death or Readmission in the 12 Months Following a Hospital Admission for Asthma. International Journal of Epidemiology, 1992, 21, 737-744.	0.9	166
429	The site of disruption of the bronchial epithelium in asthmatic and non-asthmatic subjects Thorax, 1992, 47, 499-503.	2.7	125
430	Albuterol and deaths from asthma in New Zealand from 1969 to 1976: A case-control study. Clinical Pharmacology and Therapeutics, 1992, 51, 566-571.	2.3	16
431	Worldwide worsening wheezingâ $\in$ "is the cure the cause?. Lancet, The, 1992, 339, 814.	6.3	7
432	The use of a videotaped questionnaire for studying asthma prevalence. Medical Journal of Australia, 1992, 157, 311-314.	0.8	37

#	Article	IF	CITATIONS
433	Comparison of a video questionnaire* with the IUATLD written questionnaire for measuring asthma prevalence. Clinical and Experimental Allergy, 1992, 22, 561-568.	1.4	100
434	β2-agonists in asthma. Lancet, The, 1991, 337, 43-46.	6.3	11
435	β2-agonists and New Zealand asthma mortality. Lancet, The, 1991, 337, 982-983.	6.3	2
436	Cellular Events in the Bronchi in Mild Asthma and after Bronchial Provocation. The American Review of Respiratory Disease, 1989, 139, 806-817.	2.9	1,127
437	SUBEPITHELIAL FIBROSIS IN THE BRONCHI OF ASTHMATICS. Lancet, The, 1989, 333, 520-524.	6.3	1,006
438	Unsuitability of the Human Erythrocyte as a Model for in Vivo Sodium Transport Activation by Beta2 Adrenergic Agonists. Annals of Clinical Biochemistry, 1989, 26, 444-446.	0.8	1
439	The mediator and cellular basis of the allergic response. Allergy: European Journal of Allergy and Clinical Immunology, 1988, 43, 26-29.	2.7	3
440	Viral respiratory tract infection and exacerbations of asthma in adult patients Thorax, 1988, 43, 679-683.	2.7	147
441	The Contribution of Histamine to Immediate Bronchoconstriction Provoked by Inhaled Allergen and Adenosine 5′ Monophosphate in Atopic Asthma. The American Review of Respiratory Disease, 1987, 136, 369-373.	2.9	189
442	The pathogenesis and significance of bronchial hyper-responsiveness in airways disease. Clinical Science, 1987, 73, 561-572.	1.8	112
443	The Role of Histamine in Allergen and Adenosine-Induced Bronchoconstriction. International Archives of Allergy and Immunology, 1987, 82, 292-294.	0.9	31
444	BENZALKONIUM CHLORIDE AND BRONCHOCONSTRICTION. Lancet, The, 1986, 328, 1227.	6.3	8